Eli Lilly Falls 5% — FDA Oral Obesity Pill Decision and Novo Nordisk Rivalry Weigh on Shares

1 hour ago 2

David Moadel

Tue, March 17, 2026 astatine 11:27 AM CDT 5 min read

Eli Lilly (LLY) is down to the $937 country arsenic investors await an April FDA determination connected its oral obesity pill, orforglipron.
Moreover, shares of Eli Lilly rival Novo Nordisk (NVO) are down 25% twelvemonth to day arsenic contention successful the oral GLP-1 abstraction intensifies.
The LLY banal selloff reflects convergence of regulatory uncertainty astir orforglipron support timing combined with elevated unit from Novo Nordisk.
A caller survey identified 1 azygous wont that doubled Americans’ status savings and moved status from dream, to reality. Read much here.

Eli Lilly (NYSE:LLY) banal is down 5% successful Tuesday day trading, with shares falling to $937 from a anterior adjacent of $989.12. The determination adds to a unsmooth agelong for the stock, which is present down 13% twelvemonth to day from $1,072.90 astatine the commencement of 2026.

The selloff reflects a convergence of pressures: mounting anticipation astir an FDA determination connected Lilly's oral obesity pill, caller competitory sound from Novo Nordisk (NYSE:NVO) successful the oral GLP-1 space, and lingering concerns astir compounded tirzepatide products. None of these are caller stories, but unneurotic they are weighing connected a banal that had already retreated sharply from its 52-week precocious of $1,132.06.

Read: Data Shows One Habit Doubles American’s Savings And Boosts Retirement

Most Americans drastically underestimate however overmuch they request to discontinue and overestimate however prepared they are. But information shows that people with 1 habit person much than treble the savings of those who don’t.

The superior catalyst contiguous is capitalist anxiousness astir the timing and result of the FDA's expected determination connected orforglipron, Lilly's oral GLP-1 obesity pill. Lilly submitted orforglipron for obesity support successful the U.S. and Japan, and for some obesity and benignant 2 diabetes successful the EU, with CEO David Ricks citing the submission arsenic a "key 2025 milestone." An April determination model has been wide discussed, and markets are pricing successful meaningful uncertainty astir some timing and statement scope.

Phase 3 information showed patients maintained value nonaccomplishment aft switching from injectable incretin therapies to the oral pill, a uncovering that could meaningfully grow the addressable marketplace for patients who defy injections. Yet, the support way inactive carries execution risk, and prediction markets presently delegate lone 22% probability to FDA support of Lilly's retatrutide (a related obesity candidate) by the extremity of 2026; this reflects broader skepticism astir near-term regulatory timelines crossed Lilly's obesity pipeline.

Read Entire Article